Sometimes it's important to keep calm and just stay invested. I'm just annoyed that I didn't buy more. But I don't want to complain on a day like this. Always stay modest.
🧬 Summary of the report
🚀 Share reaction
- The share of Corcept Therapeutics (CORT) jumped by 45 % upwards.
- This was triggered by the success of the phase 3 trial ROSELLA for the drug Relacorilant against platinum-resistant ovarian cancer.
🩺 Study results
- Primary endpoint achieved:
Overall survival (OS). - Risk of death decreased by 35 % with combination Relacorilant + Nab-Paclitaxel vs. chemotherapy alone.
- Median overall survival:
- Combination: 16.0 months
- Monotherapy: 11.9 months → +4.1 months advantage
- It was previously reported that the second primary endpoint was also achieved: Progression-free survival (PFS) with 30 % lower risk for disease progression.
🧪 Safety
- Side effects were comparable with standard therapy.
- No new safety concerns → good tolerability.
🏛️ Regulatory status
- FDA is reviewing the approval application, decision date: July 11, 2026.
- EMA is also reviewing a marketing authorization.
🔭 Pipeline outlook
- Relacorilant is also being investigated in studies on other solid tumors: platinum-sensitive ovarian cancer, endometrial, cervical, pancreatic and prostate cancer.
